Patents by Inventor Bryan K. Chan

Bryan K. Chan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF
    Publication number: 20220370420
    Abstract: Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.
    Type: Application
    Filed: March 17, 2021
    Publication date: November 24, 2022
    Applicant: Genentech, Inc.
    Inventors: Sushant Malhotra, Craig Stivala, BinQing Wei, Bryan K. Chan, Timothy Heffron, Michael Lainchbury, Andrew Madin, Terry Aaron Panchal, Eileen Mary Seward, Toby Blench, Matthew W. Cartwright, Elsa Amandine Dechaux, Richard Elliott, Emanuela Gancia
  • CINNOLINE COMPOUNDS AND USES THEREOF
    Publication number: 20220073520
    Abstract: Cinnoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.
    Type: Application
    Filed: March 26, 2021
    Publication date: March 10, 2022
    Applicant: Genentech, Inc.
    Inventors: Sushant Malhotra, Michael Siu, Weiru Wang, BinQing Wei, Aihe Zhou, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • NAPHTHYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20210277024
    Abstract: Naphthyridine compounds of formula (I). variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Application
    Filed: January 22, 2021
    Publication date: September 9, 2021
    Applicant: Genentech, Inc.
    Inventors: Terry Kellar, Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • ISOQUINOLINE COMPOUNDS AND USES THEREOF
    Publication number: 20210253580
    Abstract: Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
    Type: Application
    Filed: January 22, 2021
    Publication date: August 19, 2021
    Applicant: Genentech, Inc.
    Inventors: Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Joy Alison Drobnick, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • Pyrazole aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 9212173
    Abstract: Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: December 15, 2015
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Bryan K. Chan, Mark Chambers, Huifen Chen, Anthony Estrada, Zachary Kevin Sweeney
  • Bicyclic pyrazole LRRK2 small molecule inhibitors
    Patent number: 9212186
    Abstract: Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3 and A are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: December 15, 2015
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Bryan K. Chan, Jennafer Dotson, Anthony Estrada, Timothy Heffron, Joseph Lyssikatos, Zachary Sweeney
  • Aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 9145402
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: September 29, 2015
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Mark Chambers, Bryan K. Chan, Anthony Estrada, Daniel Shore, Zachary Kevin Sweeney, Huifen Chen
  • Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (PET) imaging for LRRK2
    Patent number: 9139566
    Abstract: A method for positron emission tomography (PET) imaging of LRRK2 in tissue of a subject, the method comprising: administering a compound of formula I, formula II or formula III, or a pharmaceutically acceptable salt thereof to the subject, wherein the compound includes at least one C11 or F18 label thereon; allowing the compound to penetrate into the tissue of the subject; and collecting a PET image of the CNS or brain tissue of the subject.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: September 22, 2015
    Assignee: Genentech, Inc.
    Inventors: Jan Marik, Zachary Kevin Sweeney, Bryan K. Chan, Anthony Estrada
  • BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS
    Publication number: 20150051201
    Abstract: Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3 and A are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 19, 2015
    Applicant: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Bryan K. Chan, Jennafer Dotson, Anthony Estrada, Timothy Heffron, Joseph Lyssikatos, Zachary Sweeney
  • PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS
    Publication number: 20150051238
    Abstract: Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 19, 2015
    Applicant: GENENTECH, INC.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Bryan K. Chan, Mark Chambers, Huifen Chen, Anthony Estrada, Zachary Kevin Sweeney
  • Pyrazole aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 8815882
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: August 26, 2014
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Zachary Kevin Sweeney
  • Aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 8809331
    Abstract: Specific Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein m, X, R1, R2, R3, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: August 19, 2014
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Janet L. Gunzner-Toste, Daniel Shore, Zachary Kevin Sweeney, Shumei Wang, Guiling Zhao
  • Aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 8802674
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: August 12, 2014
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Janet Gunzner-Tate, Daniel Shore, Zachary Kevin Sweeney, Shumei Wang, Guiling Zhao
  • Aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 8796296
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: August 5, 2014
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Mark Chambers, Bryan K. Chan, Anthony Estrada, Zachary Kevin Sweeney
  • Aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 8791130
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: July 29, 2014
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Mark Chambers, Bryan K. Chan, Anthony Estrada, Zachary Kevin Sweeney
  • Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK
    Patent number: 8569281
    Abstract: The present invention relates to substituted pyrazolopyridine compounds, and pharmaceutically acceptable salts or esters thereof. The present invention further relates to therapeutic uses of pharmaceutical compositions comprising the substituted pyrazolopyridine compounds, for example, in cancer and neurodegenerative diseases.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: October 29, 2013
    Assignees: Medical Research Council Technology, Genentech, Inc.
    Inventors: Bryan K. Chan, Huifen Chen, Anthony Estrada, Daniel Shore, Zachary Sweeney, Edward Giles McIver
  • Aminopyrimidine derivatives as LRRK2 inhibitors
    Patent number: 8354420
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: January 15, 2013
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Janet Gunzner-Toste, Daniel Shore, Zachary Sweeney, Shumei Wang, Guiling Zhao
  • COMPOUNDS
    Publication number: 20120295883
    Abstract: The present invention relates to substituted pyrazolopyridine compounds, and pharmaceutically acceptable salts or esters thereof. The present invention further relates to therapeutic uses of pharmaceutical compositions comprising the substituted pyrazolopyridine compounds, for example, in cancer and neurodegenerative diseases.
    Type: Application
    Filed: September 21, 2011
    Publication date: November 22, 2012
    Applicants: GENENTECH, INC., MEDICAL RESEARCH COUNCIL TECHNOLOGY
    Inventors: Bryan K. CHAN, Huifen CHEN, Anthony ESTRADA, Daniel SHORE, Zachary SWEENEY, Edward Giles MCIVER
  • PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS
    Publication number: 20120157427
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Application
    Filed: November 9, 2011
    Publication date: June 21, 2012
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Zachary Kevin Sweeney
  • AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS
    Publication number: 20110301141
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Application
    Filed: June 1, 2011
    Publication date: December 8, 2011
    Applicant: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Janet Gunzner-Toste, Daniel Shore, Zachary Sweeney, Shumei Wang, Guiling Zhao